Casma Therapeutics (United States)
Casma is a new kind of degradation company focused on the autophagy pathway. Developed through our extensive expertise in cell biology and unique drug discovery capabilities, our highly differentiated discovery engine identifies important autophagy disease targets beyond singular proteins. Our PHLYT™ platform allows us to permanently eliminate these disease-causing elements inside cells.
Basic Information
- Category: business
- Website: https://www.casmatx.com/
Documented Facts
- Phone: (857) 777-4990 (No linked source recorded for this statement.)
- Email: contact@casmatx.com (No linked source recorded for this statement.)
- Founded: 2018 (No linked source recorded for this statement.)
- Headquarters: Cambridge, MA, our team of experts in molecular biology and drug discovery is developing a technology that reprograms the autophagy pathway to degrade disease targets (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Casma Therapeutics (United States).
- Canonical profile: https://brandsource.ai/brands/casma-therapeutics-united-states
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/casma-therapeutics-united-states/json-ld
- Citation profile API: https://brandsource.ai/api/brands/casma-therapeutics-united-states/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (90/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Casma is a new kind of degradation company focused on the autophagy pathway. Developed through our extensive expertise in cell biology and unique drug discovery capabilities, our highly differentiated discovery engine identifies important autophagy disease targets beyond singular proteins. Our PHLYT™ platform allows us to permanently eliminate these disease-causing elements inside cells.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.